



UP-1646
#10/8/2001
9-6-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Farb et al.

Application No.: 09/652,345

Filing Date: August 31, 2000

Title: EFFECT OF STEROIDS ON NMDA RECEPTORS DEPENDS ON SUBUNIT
COMPOSITION

Examiner: Li, R.

Art Unit: 1646

RECEIVED
SEP 05 2001
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with
the United States Postal Service as First Class Mail in an envelope
addressed to Honorable Commissioner of Patents and Trademarks,
Washington, D.C. 20231 on 8/30/01
FARRELL & ASSOCIATES, P.C.

Sammy Thibault 8/30/01

RESPONSE TO NOTICE TO COMPLY AND AMENDMENT TO
INCORPORATE SEQUENCE LISTING

Commissioner of Patents
Washington, DC 20231

Sir:

On July 30, 2001, a NOTICE TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO
ACID SEQUENCE DISCLOSURES (referred to herein as NOTICE TO COMPLY)
was mailed from the Patent Office. This paper is filed in response
to the Notice to Comply. Please amend the application as described
below.

In the Figures:

Please delete Figure 23 and substitute therefor attached new Figure 23.


In the Specification:

Please insert the attached Sequence Listing after page 78 of the specification, and renumber the claims pages to begin with 83.

REMARKS

In response to the Notice to Comply, attached is a Sequence Listing. Also transmitted herewith is a copy of the Sequence Listing in computer readable form. As required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d) Applicants' Attorney hereby states that the content of the Sequence Listing in paper form and on the computer readable form of the Sequence Listing are the same, and the submission includes no new matter.

Respectfully submitted,



Kevin M. Farrell
Attorney for Applicant
Registration No.: 35,505
(207) 363-0558

Dated: 8/30/01
York Harbor, Maine 03911

Application No.: 09/652,345

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-308-6900

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

TECH CENTER 1600/2900

SEP 05 2001

RECEIVED